creating knowledge for future



High Quality


Scholarly Publishing
                CAREER NETWORK  
         
World's one of the largest Research
Career Network
Benefits
  •     Academic & Industry jobs
  •     Project funding
  •     Visiting faculty positions
  •     Visiting scientist positions
  •     Invited talks
  •     and more...  
   
Register FREE  
 
 
 
 
 
  Journal of Nanoscience Letters 2013, 3: 8
  Research Article
 
Magnetic polycaprolactone nanoparticles for anticancer drug delivery
  Rajesh Patela, Asifkhan Shanavasa, Mohammed Aslamc, Dhirendra Bahadurb, Rohit Srivastavaa  
     
a Department of Biosciences and Bioengineering, IIT Bombay, Powai, Mumbai, India
b Department of Metallurgical Engineering and Materials Science, IIT Bombay, Powai, Mumbai, India
c Department of Physics, IIT Bombay, Powai, Mumbai, India

   
  Abstract  
  In this study, oleic acid capped magnetic nanoparticles were prepared by a co-precipitation method reported elsewhere. Docetaxel and magnetic nanoparticle co-loaded polycaprolactone nanoparticles were prepared by solvent diffusion method using surfactant F68. Particle size was measured by DLS and verified using HRTEM. FTIR study was used to confirm oleic acid coating on to the magnetic nanoparticles. XRD study was used to confirm crystallinity of magnetic nanoparticles. VSM study was performed to check magnetic property of nanoparticles. High encapsulation efficiency (~70%), burst and sustained release profile of the chosen formulation were established using docetaxel as a model hydrophobic drug. The drug unloaded formulation was found to be biocompatibile (~90% cell viability using L929 mouse fibroblast cell line). Drug loaded formulation produced equivalent cytotoxicity in the MCF7 breast cancer cells as that of free drug. We therefore, conclude that magnetic polycaprolactone nanoparticles can be used as a promising anticancer drug delivery system in the field of cancer therapy.
     
  Keywords  
  Magnetic nanoparticles (MNPs); Polycaprolactone nanoparticles (PCLNs); Magnetic polycaprolactone nanoparticles; Docetaxel  
     
   
   
   
   
     

  © 2016 Cognizure